Clinical Trials
-
This study is designed to determine the role of specific genes in obesity and/or type 2 diabetes mellitus. Patients who are severely obese, and/or with an onset of type 2 diabetes at less than 25 years of age. Ideally, we would like to have families involved in this study. The ideal family is one in which NOT everyone in the family is obese or diabetic. Families in which one or neither parent is obese/diabetic, and some but not all children are obese/diabetic, are ideal.
-
The goal of this study is to better understand the genetic causes of weight gain and identify individuals who may benefit from a new treatment to help them maintain a healthy weight. Your participation will help us understand how why some people gain more weight and how individuals can stay at a healthy weight. We will ask you questions about your weight and your height to determine if you are eligible. If you are eligible, we will invite you to participate.
-
Principal Investigator
Cindy Neunert, MDThe purpose of this study is investigate the safety and effectiveness of eltrombopag (investigational drug) in treating children and adolescents with newly-diagnosed immune thrombocytopenia (ITP), which is a rare blood disorder. -
Research funded by the NIH is being done to learn if an asthma medication, given along with standard asthma care, makes children less likely to have asthma attacks.
-
In this trial, we will evaluate whether partially-HLA matched allogeneic multivirus-specific VSTs, will be safe and produce anti-viral effects in immunodeficient recipients infected with one of more of the targeted viruses that are persistent despite conventional anti-viral therapy. This will be in patients who have received a hematopoietic stem cell transplant or patients with primary immunodeficiency conditions who have persistent viral infections and have not undergone HSCT.
-
The purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children and young adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) which has come back or has not responded to standard therapy. Palbociclib is considered experimental because it has not been approved by the United States (US) Food and Drug Administration (FDA) for treating children with Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). Palbociclib works by targeting proteins that are necessary for cell growth.
-
This research study is being conducted to study pulmonary hypertension and right heart dysfunction based on clinical, imaging, physiological and pathological characteristics. We hope to develop a new classification system and new methods to diagnose and treat pulmonary hypertension. Diagnostic testing includes (listed subsequently): full medical work-up, minimal blood collection, right heart catheterization, echocardiogram, ekg, take home sleep oximetry study, six-minute walk, exercise test, Pulmonary function test, Lung CT, Questionnaires, ventilation/perfusion scan and cardiac MRI.
-
Asthma registry to maintain and expand a database of participants with asthma who may be able to participate in future Inner City Asthma Consortium studies.
-
The purpose of this study is to find out the effects and safety of an investigational (experimental) new drug called copanlisib in pediatric patients from 6 months to 21 years of age. This study consists in two phase, Phase I part will determine which is the right dose of copanlisib to be used in children/adolescents/adults with relapsed (has returned) or refractory (did not respond to standard treatment) solid tumor or lymphoma.
-
The purpose of this study is to find out the effects and safety of an investigational (experimental) new drug called copanlisib in pediatric patients from 6 months to 21 years of age. This study consists in two phase, Phase I part will determine which is the right dose of copanlisib to be used in children/adolescents/adults with relapsed (has returned) or refractory (did not respond to standard treatment) solid tumor or lymphoma.